Rituximab
Monoclonal antibody targets MS4A1
Regulatory milestones approvals, filings & regulatory actions · 19 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | RUXIENCE | — | 2020-05-26 – 2021-11-15 | fda.gov ↗ |
| Label expansions (13) | US (FDA) | RITUXAN | — | 2006-02-10 – 2020-08-28 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | TRUXIMA | — | 2019-05-23 – 2019-12-18 | fda.gov ↗ |
| Approved | EU (EMA) | MabThera | — | 1998-06-02 | europa.eu ↗ |
| Approved | US (FDA) | RITUXAN | — | 1997-11-26 | fda.gov ↗ |
Trials 1,447 · started per year
Press releases naming this drug 187 releases
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 2,367 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rituximab | “Patients initially received one 21-day cycle of standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP; rituximab 375 mg/m2, cyclophosphamide...” PMID 30948276 ↗ Apr 20192298“All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone)...” NCT05874778 ↗ “A Phase 3 Open Label Multicenter, Randomized Study to Compare the Efficacy and Safety of the Zevalin (Ibritumomab Tiuxetan) Therapeutic Regimen Following Cyclophosphamide,...” NCT00384111 ↗ “Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone...” NCT01460602 ↗ “This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients...” NCT04546620 ↗ “The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and...” NCT01393756 ↗ “All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m²,...” NCT03399513 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗ “Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with...” NCT03123718 ↗ “rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab...” NCT00581854 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗ |
| Known as | ABP 798 | “ABP 798” NCT03096782 ↗ |
| Known as | CT-P10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02162771 ↗ |
| Known as | EU-rituximab | “Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion” NCT04268771 ↗ |
| Known as | EU-RTX | “Adults with active RA were treated with CT-P10, United States-sourced RTX (US-RTX; Rituxan®), or European Union-sourced RTX (EU-RTX; MabThera®) at weeks 0 and 2.” PMID 30010481 ↗ Jul 2018 |
| Known as | Halpryza | “Participants who experience life-threatening toxicities caused by uncontrollable proliferation of fhB7H3.CAR-Ts will receive infusion of Rituximab (Rituxan or Ruxience or Halpryza)” NCT05211557 ↗ |
| Known as | IDEC-102 | “Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens” NCT00090038 ↗1“Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)” NCT00168740 ↗ |
| Known as | IDEC-C2B8 | “The double-blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic sclerosis (DesiReS) trial showed...” PMID 35136981 ↗ Nov 20229“A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having...” NCT00003280 ↗ “Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA)” NCT00003757 ↗ “Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)” NCT00168740 ↗ “Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma” NCT01939730 ↗ “rituximab (IDEC-C2B8 monoclonal antibody; anti-CD20 monoclonal antibody)” NCT00003397 ↗ “chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction.” NCT00003248 ↗ “rituximab (IDEC-C2B8 monoclonal antibody)” NCT00003605 ↗ “Drug: rituximab / IDEC-C2B8” NCT02265731 ↗ “IDEC-C2B8 (rituximab)” NCT00298272 ↗ |
| Known as | intrathecal rituximab (Mabthera) | “intrathecal rituximab (Mabthera)” NCT02545959 ↗ |
| Known as | LD-RTX | “all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) with LD-RTX monotherapy” PMID 34665865 ↗ Jan 2022 |
| Known as | Mabthera | “An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine®) Associated With RCHOP Chemotherapy and...” NCT00896519 ↗90“This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa...” NCT01611259 ↗ “A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having...” NCT00003280 ↗ “Treatment with \[90Y\]-ibritumomab tiuxetan is preceded by an infusion of rituximab (Rituxan, Mabthera) in order to optimize the biodistribution of radiolabeled antibody by...” NCT00859001 ↗ “Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison...” NCT00140582 ↗ “Treatment with [90Y]-ibritumomab tiuxetan is preceded by an infusion of rituximab (Rituxan, Mabthera) in order to optimize the biodistribution of radiolabeled antibody by...” NCT00850512 ↗ “OBJECTIVE: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01 (a rituximab biosimilar) and reference rituximab sourced from China...” PMID 34321836 ↗ Jun 2021 “Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following...” NCT00005589 ↗ “The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders.” PMID 24265828 ↗ Nov 2013 “Treatment: Controlled ovarian hyperstimulation before and four months after an infusion of 1-gram rituximab (Mabthera®) twice with two weeks interval.” NCT05586737 ↗ “A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.” NCT02468791 ↗ |
| Known as | mabthera equals Rituximab | “mabthera equals Rituximab” NCT01134432 ↗ |
| Known as | MabThera for Rituximab | “MabThera for Rituximab” NCT05063513 ↗ |
| Known as | Mabthera(R) | “systemic treatment with the anti CD20 antibody Rituximab (Mabthera(R)) in combination with involved field radiotherapy” NCT00509184 ↗ |
| Known as | MabThera/Rituxan | “MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy” NCT01649856 ↗1“MabThera/Rituxan” NCT01126541 ↗ |
| Known as | NSC #687451 | “Randomized Phase III Trial Of Rituximab (NSC #687451) And Autologous Stem Cell Transplantation For B Cell Diffuse Large Cell Lymphoma” NCT00052923 ↗1“Chimeric Anti-CD20 Monoclonal Antibody IDEC-C2B8 (Rituximab) [NSC# 687451] Induction” NCT00003248 ↗ |
| Known as | PBO-326 | “PBO-326 (Rituximab)” NCT01277172 ↗ |
| Known as | Radiotherapy, rituximab and DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01926639 ↗ |
| Known as | Ristova | “Participants will be treated with rituximab (Ristova) and glucocorticoids.” NCT02115997 ↗ |
| Known as | RIT | “We aimed to compare the efficacy of azathioprine (AZA) and rituximab (RIT) as maintenance therapy in NMOSD patients.” PMID 28831548 ↗ Aug 2017 |
| Known as | Rituxan | “Treatment with \[90Y\]-ibritumomab tiuxetan is preceded by an infusion of rituximab (Rituxan, Mabthera) in order to optimize the biodistribution of radiolabeled antibody by...” NCT00859001 ↗82“The goal of this clinical research is to see if Rituxan (rituximab) therapy given after high dose chemotherapy and transplant of a patients own stem cells will prevent or delay...” NCT01103388 ↗ “This is a Phase I/II , single agent study which will evaluate the safety and feasibility of subcutaneous rituximab (Rituxan) administered at 20 mg/day three times a week for 12...” NCT00366418 ↗ “Treatment with [90Y]-ibritumomab tiuxetan is preceded by an infusion of rituximab (Rituxan, Mabthera) in order to optimize the biodistribution of radiolabeled antibody by...” NCT00850512 ↗ “The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other...” NCT00078234 ↗ “Participants who experience life-threatening toxicities caused by uncontrollable proliferation of fhB7H3.CAR-Ts will receive infusion of Rituximab (Rituxan or Ruxience or Halpryza)” NCT05211557 ↗ “The purpose of this study is to reduce the symptoms of OMS by testing rituximab (Rituxan®), to remove B lymphocytes that make antibodies and trigger brain inflammation.” NCT00244361 ↗ “Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT” NCT00648037 ↗ “The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders.” PMID 24265828 ↗ Nov 2013 “A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan® for Patients With Relapsed or Refractory, Follicular Lymphoma” NCT00048555 ↗ “In this research study, the investigators are adding the drug rituximab (Rituxan) to the drug cytarabine for the stem cell mobilization process.” NCT01182415 ↗ |
| Known as | Rituxan (rituximab) | “Rituxan (rituximab)” NCT00783367 ↗ |
| Known as | RITUXAN (Trademark) | “This study will test whether rituximab (RITUXAN (Trademark)) can relieve symptoms of stiff person syndrome (SPS), a progressive disease that causes stiffness of the muscles and...” NCT00091897 ↗ |
| Known as | Rituxan(R), MabThera(R) = Rituximab | “Rituxan(R), MabThera(R) = Rituximab” NCT00991211 ↗ |
| Known as | Rituximab (Mabthera) | “Rituximab (Mabthera)” NCT00644371 ↗4“Rituximab (MabThera)” NCT01307605 ↗ “Rituximab (Mabthera)” NCT00646750 ↗ “Rituximab (MabThera)” NCT00937131 ↗ “Rituximab: MABTHERA” NCT01185262 ↗ |
| Known as | Rituximab (Mabthera; Rituxan) 375 mg/m² | “Rituximab (Mabthera®; Rituxan®) 375 mg/m²” NCT02157181 ↗ |
| Known as | Rituximab (Rituxan) | “rituximab (Rituxan®)” NCT04047628 ↗4“Rituximab (Rituxan)” NCT00250926 ↗ “Rituximab (Rituxan)” NCT01527422 ↗ “Rituximab - Rituxan” NCT01001780 ↗ “Rituximab:Rituxan” NCT01449344 ↗ |
| Known as | Rituximab Biosimilar RTXM83 | “Rituximab Biosimilar RTXM83” NCT03096782 ↗ |
| Known as | rituximab biosimilar TQB2303 | “rituximab biosimilar TQB2303” NCT02727803 ↗ |
| Known as | rituximab IDEC-C2B8 | “rituximab IDEC-C2B8” NCT00089284 ↗ |
| Known as | RiTUXimab Injection | “Drug: RiTUXimab Injection” NCT06341205 ↗ |
| Known as | rituximab-abbs | “rituximab-abbs” NCT02727803 ↗ |
| Known as | rituximab-CN | “OBJECTIVE: This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01 (a rituximab biosimilar) and reference rituximab sourced from China...” PMID 34321836 ↗ Jun 2021 |
| Known as | rituximab-EU | “MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22” NCT02213263 ↗ |
| Known as | Rituximab-pvvr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03929601 ↗ |
| Known as | Rituximab=CT-P10 | “Rituximab=CT-P10” NCT01873443 ↗ |
| Known as | RTX | “In vitro, immune complexes (ICx) trigger NET formation while NET-derived DNA is a postulated autoantigen for anti-nuclear autoantibodies (ANAs), found in SLE. Based on these...” PMID 29636274 ↗ Apr 201830“OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at...” NCT01673295 ↗ “Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic...” PMID 36130755 ↗ Sep 2022 “A pilot study previously demonstrated that thrice-weekly, fractionated-dose intravenous rituximab (RTX) limits CD20 loss from chronic lymphocytic leukemia (CLL) B cells,...” PMID 19679883 ↗ Aug 2009 “To assess the maximum tolerated dose (MTD) of temozolomide (TMZ) in combination with methotrexate (MTX) and rituximab (RTX) when administered prior to twice daily fractionated...” NCT00068250 ↗ “Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that depletes B cells and is effective in numerous autoimmune diseases including antineutrophil cytoplasmic antibody...” PMID 21325353 ↗ Feb 2011 “CT-P10 is a biosimilar of innovator rituximab (RTX), a biological therapy used to treat patients with rheumatoid arthritis (RA) who have responded inadequately to anti-tumor...” PMID 28612179 ↗ Aug 2017 “OBJECTIVE: To characterize the safety of rituximab (RTX) in combination with biologic disease-modifying antirheumatic drugs (DMARD) in patients with rheumatoid arthritis (RA).” PMID 23547218 ↗ Apr 2013 “prospectively evaluate the efficacy and safety of rituximab (RTX) versus placebo in a broad range of progressive ILD outside sarcoidosis and connective tissue diseases.” PMID 39693827 ↗ Nov 2024 “Patients were randomized to either TNFi (infliximab, INF), anti-IL-6 (tocilizumab, TCZ), CTLA4-Ig (abatacept, ABA) or anti-CD20 (rituximab, RTX) in addition to MTX.” PMID 34792562 ↗ Jul 2022 “Rituximab (RTX) is commonly used in SSc-ILD induction treatment and recent trials have now fully demonstrated its safety and efficacy as an induction treatment.” NCT07827742 ↗ |
| Known as | RTX-EU | “Rituxan® [RTX-US] and MabThera® [RTX-EU]” PMID 32052313 ↗ Apr 2020 |
| Known as | RTX-US | “Rituxan® [RTX-US] and MabThera® [RTX-EU]” PMID 32052313 ↗ Apr 2020 |
| Known as | RTXM83 | “RTXM83” NCT02727803 ↗ |
| Known as | Ruxience | “Participants who experience life-threatening toxicities caused by uncontrollable proliferation of fhB7H3.CAR-Ts will receive infusion of Rituximab (Rituxan or Ruxience or Halpryza)” NCT05211557 ↗ |
| Known as | Truxima | “Rituximab (Truxima) 375mg/m2 IV Weekly (X4)” NCT03578198 ↗5“Drug: RiTUXimab Injection [Truxima]” NCT05191225 ↗ “TRUXIMA®” NCT07634471 ↗ “Truxima” NCT02727803 ↗ “Truxima” NCT04189588 ↗ |
| Known as | US-rituximab | “Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion” NCT04268771 ↗ |
| Known as | US-RTX | “Adults with active RA were treated with CT-P10, United States-sourced RTX (US-RTX; Rituxan®), or European Union-sourced RTX (EU-RTX; MabThera®) at weeks 0 and 2.” PMID 30010481 ↗ Jul 2018 |
| Known as | ◦Drug: Rituximab | “◦Drug: Rituximab” NCT01983761 ↗ |
| Action | Deplete | “Rituximab, a CD20 monoclonal antibody, may result in eradication of the monoclonal B cells.” PMID 18067008 ↗ Dec 2007 |
| Modality | Monoclonal antibody | “rituximab, the humanized monoclonal antibody against the CD20 receptor” NCT00001337 ↗ |
| Route | Intravenous | “Rituximab 375 mg/m\^2 intravenous (IV) on day 1” NCT00001337 ↗ |
| Target | CD20 | “Chimeric Anti-CD20 Antibody” NCT05052528 ↗ |